4-氯-2-氯甲基-1-甲氧基苯 | 7035-11-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯-2-氯甲基-1-甲氧基苯
• 英文名称: 4-chloro-2-chloromethyl-1-methoxy-benzene
• 英文别名: 4-Chloro-2-(chloromethyl)-1-methoxybenzene
• CAS: 7035-11-2
• 化学式: C₈H₈Cl₂O
• mdl: MFCD02182262
• 分子量: 191.057
• InChiKey: UWRGQGVLSLNMLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2909309090
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Chloro-2-(chloromethyl)-1-methoxybenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Chloro-2-(chloromethyl)-1-methoxybenzene
CAS number: 7035-11-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8Cl2O
Molecular weight: 191.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-2-氯甲基-1-甲氧基苯 在 aluminum tri-bromide 、 硝酸 、 magnesium 、 苯 作用下， 生成 5,5'-dichloro-3,3'-dinitro-bibenzyl-2,2'-diol
  参考文献：
  名称：

  Pfleger; Waldmann, Chemische Berichte, 1957, vol. 90, p. 2395,2399

  摘要：

  DOI：
• 作为产物：
  描述：

  5-氯-2-甲氧基苯甲酸甲酯 在 lithium aluminium tetrahydride 、 氯化亚砜 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 4-氯-2-氯甲基-1-甲氧基苯
  参考文献：
  名称：

  临床候选4- [2-（5-氨基-1 H-吡唑-4-基）-4-氯苯氧基] -5-氯-2-氟-N -1,3-噻唑-4-基苯磺酰胺（PF）的发现-05089771）：作为Na V 1.7选择性抑制剂的二芳基醚芳基磺酰胺的设计和优化

  摘要：

  描述了一系列酸性二芳基醚杂环磺酰胺，它们是有效的亚型选择性Na V 1.7抑制剂。早期铅物质的优化集中在消除结构警报，改善代谢稳定性和减少细胞色素P450抑制性驱动的药物相互作用方面，以实现临床前体外特性的理想平衡。由于对非代谢途径的清除，临床前物种中的清除程度可变以及随后的低置信度人类药代动力学预测的担忧，导致决定进行人类微剂量研究以确定临床药代动力学。描述了临床前PK和临床人微剂量PK数据的设计策略和结果，从而发现了第一个亚型选择性Na V1.7抑制剂临床候选物PF-05089771（34），其与电压感测域中的位点结合。

  DOI：

  10.1021/acs.jmedchem.7b00598

文献信息

• Carbon-halogen bond activation by a structurally constrained phosphorus(III) platform
  作者：Penglong Wang、Qin Zhu、Yi Wang、Guixiang Zeng、Jun Zhu、Congqing Zhu

  DOI：10.1016/j.cclet.2020.11.005

  日期：2021.4

  The σ-bond activation by main group element has received enormous attention from theoretical and experimental chemists. Here, the reaction of C–X (X = Cl, Br, I) bonds in benzyl and allyl halides with a pincer-type phosphorus(III) species was reported. A series of structurally robust phosphorus(V) compounds were formed via the formal oxidative addition reactions of C–X bonds to the phosphorus(III)

  通过主族元素进行的σ键活化受到了理论和实验化学家的极大关注。在这里，有报道称苄基和烯丙基卤化物中的C–X（X = Cl，Br，I）键与钳型磷（III）的反应。通过以下方法形成了一系列结构坚固的磷（V）化合物C–X键与磷（III）中心的正式氧化加成反应。密度泛函理论计算表明，亲核加成过程比直接氧化加成机理更有利。磷（III）化合物的弯曲结构异构化为亲核性较差的化合物，以进行进一步的C–X键活化作用，这可以通过前沿分子轨道分析来合理化。这项研究不仅提供了对磷（III）物种的反应性的深刻理解，而且还展示了主要基团元素对小分子活化的潜力。
• INDAZOLE DERIVATIVES
  申请人：Ackermann Jean

  公开号：US20080103182A1

  公开（公告）日：2008-05-01

  The invention is concerned with novel indazole derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used in the prevention or treatment of diseases which are modulated by L-CPT1 inhibitors.

  这项发明涉及公式（I）的新型吲唑衍生物，其中R1、R2、R3、R4、R5、R6、X和Y的定义如描述和索赔中所述，以及其生理上可接受的盐和酯。这些化合物抑制L-CPT1，可用于预防或治疗受L-CPT1抑制剂调节的疾病。
• SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES
  申请人：CHROMOCELL CORPORATION

  公开号：US20160130239A1

  公开（公告）日：2016-05-12

  Provided herein are sodium channel modulating Compounds, in particular NaV1.7 modulating compounds of Formula I or compounds of Formula I′: In particular, provided herein are processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions comprising, and therapeutic methods comprising administering such compounds. In particular, provided herein are compounds for the treatment of pain and diabetes.

  本文提供了钠通道调节化合物，特别是公式I的NaV1.7调节化合物或公式I'的化合物：特别提供了用于制备、制备中使用的中间体、包含的药物组合物以及包含给予这些化合物的治疗方法的过程。特别提供了用于治疗疼痛和糖尿病的化合物。
• NK-1 receptor active amine oxide prodrugs
  申请人：——

  公开号：US20020045642A1

  公开（公告）日：2002-04-18

  Compounds of the invention are amine oxide prodrugs showing activity on the NK1 receptor.

  该发明的化合物是氨氧化物前药，对NK1受体显示活性。
• [EN] SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES<br/>[FR] INHIBITEURS SÉLECTIFS DE NAV1.7 POUR LE TRAITEMENT DU DIABÈTE
  申请人：CHROMOCELL CORP

  公开号：WO2016040315A1

  公开（公告）日：2016-03-17

  Provided herein are methods for treating or preventing prediabetes or diabetes, or maintaining or lowering blood or plasma glucose or maintaining or lowering blood or plasma glycated hemoglobin comprising administering to a subject in need thereof a therapeutically effective amount of a compound selectively inhibiting NaVl.7. In particular, provided herein are processes for the preparation of and intermediates used in the preparation of compounds selectively inhibiting NaV1.7, such as the compounds of Formula (I) or compounds of Formula (I').

  本文提供了治疗或预防糖尿病前期或糖尿病，或维持或降低血液或血浆葡萄糖或维持或降低血液或血浆糖化血红蛋白的方法，包括向需要的受试者施用选择性抑制NaV1.7的化合物的治疗有效量。具体来说，本文提供了用于制备选择性抑制NaV1.7的化合物的方法和用于制备这些化合物的中间体，例如Formula（I）的化合物或Formula（I'）的化合物。